Kwang Jang
Internal Medicine · Chicago, ILNPI 1326271909
Payments from drug & device makers
Across 51 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$110
- Amgen$103
- Lilly USA, LLC$97
- Merck$93
- Novo Nordisk$89
- Cranial Technologies, Inc$77
- plus $343 from 15 others
What the payments were for
- Food & beverage$912100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $110 |
| Amgen | 6 | $103 |
| Lilly USA, LLC | 5 | $97 |
| Merck | 7 | $93 |
| Novo Nordisk | 1 | $89 |
| Cranial Technologies, Inc | 5 | $77 |
| Boehringer Ingelheim | 3 | $52 |
| Bayer | 2 | $43 |
| Abbott | 3 | $42 |
| AstraZeneca | 2 | $30 |
| Alkermes, Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Braeburn Inc. | 1 | $17 |
| Mannkind Corporation | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Coopersurgical, Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Mayne Pharma Commercial LLC | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$912 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 79 | $100,329 |
| JanuviaSitagliptin Phosphate | 61 | $50,442 |
| TradjentaLinagliptin | 26 | $28,312 |
| OzempicSemaglutide | 18 | $26,772 |
| FarxigaDapagliflozin Propanediol | 23 | $22,163 |
| InvokanaCanagliflozin | 26 | $21,211 |
| EliquisApixaban | 11 | $10,969 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $8,590 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,780 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $6,278 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,582 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $3,284 |
| Rosuvastatin Calcium | 113 | $3,012 |
| Novolog FlexpenInsulin Aspart | 13 | $2,445 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $2,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $52 | $128,641105 claims |
| MerckJanuvia | $93 | $50,44261 claims |
| Novo NordiskOzempic | $89 | $26,77218 claims |
| AstraZenecaFarxiga, Symbicort | $30 | $25,74538 claims |
| GSKBreo Ellipta | $110 | $6,78014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Dennis LevinsonChicago$25.3M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Mohammed KassemChicago$1.3M
- David BakerChicago$1M
- Azazuddin AhmedChicago$912K
- Daniel BergerChicago$861K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.